Skittishness over the AstraZeneca and Johnson & Johnson vaccines, analysts fear, could stoke demand for Russian- and Chinese-made shots, about which far less is known
If NDV-HXP-S proves safe and effective, flu vaccine manufacturers could potentially produce well over a billion doses of it a year.
The independent safety monitors found no serious side effects, including an increased risk of blood clots found in an EU study.
"This pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population," said CEO Stephane Bancel in a statement
The survivor harboured the virus for at least five years and then transmitted it via semen to a sex partner, researchers reported in articles published in Science and Stat. Until now, the longest the ebola virus had been known to persist in a survivor was 500 days
With eyes on China, Quad nations launch 1 bn vaccine plan, project grouping as 'vital arena for cooperation'
PM Narendra Modi said the first Quad summit shows that the group has come of age and will now remain an important pillar of stability in the region. It was attended by US president Joe Biden, Australian PM Scott Morrison and Japanese PM Yoshihide Suga
Independent of region, virus variant, or age, the vaccine protects against severe disease, death and hospitalization, Stoffers said.
The European Medicines Agency said it was recommending the COVID-19 jab for those over 18 “after a thorough evaluation” found it met the criteria for efficacy, safety and quality
JnJ's vaccine appears to be less prone than Pfizer-BioNTech's and Moderna's, to trigger the kinds of side effects that require monitoring.
The FDA said J&J's vaccine offers strong protection against serious illness, hospitalisations, and death. The company has said it expects to deliver 20 million doses to the US by the end of March
Johnson & Johnson's single-shot vaccine highly effective in preventing severe COVID-19, announces US FDA
In large clinical trials, the vaccine's efficacy against severe COVID-19 disease was 85.9 percent in the US, 81.7 percent in South Africa, and 87.6 percent in Brazil
The shots were all tested differently, and some were allowed to go into use even before they were rigorously tested.
A single-dose vaccine is a big advantage when most countries are struggling to get shots in arms more quickly.
Almost two billion doses of candidate vaccines have been secured for the Covax facility, created by the UN health agency, to ensure fair access
Moderna, which created its shots with the US National Institutes of Health, said it got the final needed results over the weekend that suggest the vaccine is more than 94 percent effective
Stamping out the coronavirus is a distinctly new challenge due to three factors: the short time frame for inoculating a huge number of people, the fact that most vaccines will require two doses, and the very low temperature at which some of the vaccines must be stored
After Johnson & Johnson, US pharma company Eli Lilly’s halts COVID-19 antibody treatment over safety concerns
Medical experts note that pauses in large clinical trials of coronavirus are not uncommon. They said its possible the bad reaction could be the result of an unrelated illness, and not the drug itself
The J&J Phase 3 trial had started recruiting participants in September 2020, with a goal of enrolling up to 60,000 volunteers across more than 200 sites in the US and around the world
Experts point out that the global distribution of a vaccine is necessary since none of us is safe until all of us are safe.
More than 100 potential COVID-19 vaccines are in various stages of development around the world.